Lawrence J Hayward Selected Research

Superoxide Dismutase

11/2009	A common property of amyotrophic lateral sclerosis-associated variants: destabilization of the copper/zinc superoxide dismutase electrostatic loop.
8/2008	Interaction of amyotrophic lateral sclerosis (ALS)-related mutant copper-zinc superoxide dismutase with the dynein-dynactin complex contributes to inclusion formation.
6/2008	Structures of the G85R variant of SOD1 in familial amyotrophic lateral sclerosis.
5/2005	Structural consequences of the familial amyotrophic lateral sclerosis SOD1 mutant His46Arg.
4/2004	Dimer destabilization in superoxide dismutase may result in disease-causing properties: structures of motor neuron disease mutants.
2/2003	Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction.
5/2002	Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase.
5/2002	Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lawrence J Hayward Research Topics

Disease

24	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2019 - 05/2002
6	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 06/2003
5	Hyperkalemic Periodic Paralysis 01/2020 - 12/2012
2	Sarcoma (Soft Tissue Sarcoma) 08/2013 - 11/2010
1	Muscular Diseases (Myopathy) 05/2024
1	Facioscapulohumeral Muscular Dystrophy 05/2024
1	Poisoning 05/2024
1	Surgical Wound Infection 05/2024
1	Disease Progression 01/2022
1	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 01/2022
1	Walker-Warburg Syndrome 01/2022
1	Huntington Disease (Huntington's Disease) 01/2018
1	Shock 10/2016
1	Muscle Weakness 12/2015
1	Myotonia 04/2008
1	Motor Neuron Disease (Primary Lateral Sclerosis) 04/2004

Drug/Important Bio-Agent (IBA)

9	Superoxide Dismutase-1IBA 01/2013 - 05/2003
8	Superoxide DismutaseIBA 11/2009 - 05/2002
8	CopperIBA 11/2009 - 05/2002
7	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2008
7	ZincIBA 11/2009 - 05/2002
3	RNA-Binding Protein FUSIBA 02/2015 - 11/2010
3	MetalsIBA 10/2009 - 05/2003
2	arseniteIBA 01/2019 - 10/2016
2	Tetrodotoxin (Tetradotoxin)IBA 12/2015 - 06/2014
2	Superoxides (Superoxide)IBA 10/2009 - 05/2002
2	Dyneins (Dynein)IBA 08/2008 - 06/2007
2	DisulfidesIBA 06/2008 - 02/2003
1	Transcription Factors (Transcription Factor)IBA 05/2024
1	6- (5- ((cyclopropylamino)carbonyl)- 3- fluoro- 2- methylphenyl)- N- (2,2- dimethylprpyl)- 3- pyridinecarboxamideIBA 05/2024
1	Albuterol (Salbutamol)FDA LinkGeneric 01/2020
1	Adrenergic Agonists (Adrenergic Receptor Agonist)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Antisense OligonucleotidesIBA 01/2018
1	OligonucleotidesIBA 01/2018
1	Sodium-Calcium ExchangerIBA 12/2015
1	Protein Isoforms (Isoforms)IBA 06/2014
1	Adenosine Triphosphatases (ATPase)IBA 12/2012
1	Nucleic AcidsIBA 04/2011
1	Carrier Proteins (Binding Protein)IBA 04/2011
1	Thyroglobulin FDA Link 04/2009
1	Dynactin ComplexIBA 08/2008
1	PotassiumIBA 04/2008
1	Sodium Channels (Sodium Channel)IBA 04/2008
1	Detergents (Detergent)IBA 03/2008
1	Cysteine (L-Cysteine)FDA Link 05/2007

Therapy/Procedure

5	Therapeutics 01/2022 - 01/2005